



Intercell signs license agreement with newly founded Pelias AG

Vienna (Austria), December 9, 2005 – Intercell AG today announced the signing of an exclusive license agreement with Pelias Biomedical Development AG (Pelias) in the field of hospital-acquired infections. The vaccine company Pelias has been founded recently as a new biotech startup by Intercell and partners including Chiron, Parteurop, BioAlliance and Kapital&Wert Group.

The license agreement will give Pelias access to certain antigens, targeting important pathogens in hospital infections, which have been identified by Intercell's proprietary Antigen Identification Program (AIP®). Together with the license, certain early stage preclinical development assets in the license field will be transferred from Intercell to Pelias. Intercell will receive an up-front consideration and royalty payments on future product sales. In addition, Intercell holds a major stake of shares in Pelias.

Through this license, together with a clinical stage Pseudomonas vaccine candidate, which was licensed from Chiron, Pelias will be positioned as an emerging specialist in vaccines and antibody-based therapies for the prevention and treatment of hospital-acquired infections. Pelias has received initial funding from Intercell and Kapital&Wert Group and is seeking further venture capital funding.

Werner Lanthaler, Intercell's CFO, explains the strategy behind the Pelias deal: „Our Antigen Identification technology provides us with a lot more vaccine targets than we can support in our development pipeline - some of them are partnered with major vaccine companies like Merck&Co., Inc. and sanofi pasteur. The Pelias deal provides us with the same upside in terms of future royalties, but combined with an equity stake in an attractive early stage company, that is ideally positioned to raise external funding from the venture markets. We think this model is an efficient way to leverage the value of our vaccine technologies without increasing our own R&D spend.”

About Intercell

Intercell AG is a fast growing biotechnology company focusing on the design and development of novel vaccines for prevention and treatment of diseases with substantial unaddressed medical need. The Company's unique position is based on the combination of antigens and immunizers (adjuvants) derived from its proprietary technology platforms and its in-house GMP manufacturing facilities. Intercell's technology has been endorsed by collaborative agreements with a number of global pharmaceutical companies, including sanofi pasteur, Merck&Co., Inc., SciGen Ltd. and the Statens Serum Institut. The Company has a broad development pipeline with a vaccine for Japanese Encephalitis in Phase III, a vaccine for Hepatitis C in Phase II, a partnered Tuberculosis vaccine in Phase I and five products focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".





For more information please visit: www.intercell.com

Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2

A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

Be invited to: www.intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.